Recombinant human insulin as a solid tumor potential imaging agent: Radio-synthesis and biological evaluation

Abdelaziz, Gamal; M.A., Motaleb; N., Farouk; A. Selim, Adli

doi:10.21608/nrmj.2019.37207

Recombinant human insulin as a solid tumor potential imaging agent: Radio-synthesis and biological evaluation

Document Type : Original Article

Authors

¹ laboratoire structure et Activité des biomolécules normales et pathologiques" U1204 – INSERM - Université Evry-Val d'Essonne (UEVE)

² Labeled Compounds Department, Hot Laboratories Center, Egyptian Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt

10.21608/nrmj.2019.37207

Abstract

The aim of this study was to synthesis an imaging agent for tumor targeting. New recombinant insulin analogue was successfully produced from E. coli by recombinant DNA technique, and was well labeled with Technetium-99m with a high radiochemical yield of 93.3 ± 2.1 %. Moreover, it showed good in-vitro stability in both saline and human serum. Preclinical evaluation of Technetium-99m [^99mTc] Tc-insulin in solid tumor-bearing mice showed high accumulation in tumor tissues. The T/NT (target to non-target ratio) was of 5.4, after 60 min. of post injection (p.i). The direct intra-tumoral (I.T) injection of [^99mTc] Tc-insulin showed good retention in tumor tissues with a ratio more than 50 % after 15 min. As a result of the promising bio-distribution studies; the newly recombinant insulin showed good uptake in tumor site, which assured high concentration of insulin receptor on tumor cell surface, accompanied with high cell density of tumor cells as well. This work affords a potential radio-carrier that could be used as a good tumor marker and imaging probe via SPECT (Single Photon Emission Computed Tomography) technique, after further preclinical studies.

Keywords